A multicenter prospective phase II randomized trial of epirubicin/vinorelbine versus pegylated liposomal doxorubicin/vinorelbine as first-line treatment in advanced breast cancer. A GOIM study

被引：0
|
作者：
Patrizia Vici
Giuseppe Colucci
Francesco Giotta
Domenico Sergi
Gianfranco Filippelli
Pasquale Perri
Claudio Botti
Enrico Vizza
Armando Carpino
Laura Pizzuti
Agnese Latorre
Diana Giannarelli
Massimo Lopez
Luigi Di Lauro
机构：
[1] Regina Elena National Cancer Institute,Division of Medical Oncology B
[2] Oncologic Institute,Department of Medical and Experimental Oncology
[3] Division of Medical Oncology,Division of Surgery A
[4] S. Francesco Hospital,Division of Gynecological Oncology
[5] Regina Elena National Cancer Institute,Cardiologic Unit
[6] Regina Elena National Cancer Institute,Biostatistics Unit
[7] Regina Elena National Cancer Institute,undefined
[8] Regina Elena National Cancer Institute,undefined
来源：
Journal of Experimental & Clinical Cancer Research | / 30卷
关键词：
Anthracyclines; Lapatinib; Pegylated Liposomal Doxorubicin; Neutropenic Fever; Advanced Breast Cancer Patient;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 49 条
  • [21] A phase II, randomized, multicenter study evaluating the combination of lapatinib and vinorelbine in women with ErbB2 overexpressing metastatic breast cancer
    Wolfgang Janni
    Tomasz Sarosiek
    Boguslawa Karaszewska
    Joanna Pikiel
    Elzbieta Staroslawska
    Piotr Potemski
    Christoph Salat
    Etienne Brain
    Christian Caglevic
    Kathryn Briggs
    Michelle DeSilvio
    Luca Marini
    Christos Papadimitriou
    Breast Cancer Research and Treatment, 2014, 143 : 493 - 505
  • [22] A phase II, randomized, multicenter study evaluating the combination of lapatinib and vinorelbine in women with ErbB2 overexpressing metastatic breast cancer
    Janni, Wolfgang
    Sarosiek, Tomasz
    Karaszewska, Boguslawa
    Pikiel, Joanna
    Staroslawska, Elzbieta
    Potemski, Piotr
    Salat, Christoph
    Brain, Etienne
    Caglevic, Christian
    Briggs, Kathryn
    DeSilvio, Michelle
    Marini, Luca
    Papadimitriou, Christos
    BREAST CANCER RESEARCH AND TREATMENT, 2014, 143 (03) : 493 - 505
  • [23] A Phase II trial of the combination of vinorelbine and capecitabine as second-line treatment in metastatic breast cancer previously treated with taxanes and/or anthracyclines
    Orphanos, George
    Alexopoulos, Athanasios
    Malliou, Savvoula
    Ioannidis, George
    Ardavanis, Alexandros
    Kandylis, Constantinos
    Stavrakakis, John
    Rigatos, Gerassimos
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2010, 136 (01) : 115 - 121
  • [24] A Phase II trial of the combination of vinorelbine and capecitabine as second-line treatment in metastatic breast cancer previously treated with taxanes and/or anthracyclines
    George Orphanos
    Athanasios Alexopoulos
    Savvoula Malliou
    George Ioannidis
    Alexandros Ardavanis
    Constantinos Kandylis
    John Stavrakakis
    Gerassimos Rigatos
    Journal of Cancer Research and Clinical Oncology, 2010, 136 : 115 - 121
  • [25] Pegylated liposomal doxorubicin, 5-fluorouracil and cisplatin versus mitomycin-C, 5-fluorouracil and cisplatin for advanced gastric cancer: a randomized phase II trial
    Cascinu, Stefano
    Galizia, Eva
    Labianca, Roberto
    Ferrau, Francesco
    Pucci, Francesca
    Silva, Rosa Rita
    Luppi, Gabriele
    Beretta, Giordano Domenico
    Berardi, Rossana
    Scartozzi, Mario
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2011, 68 (01) : 37 - 43
  • [26] Pegylated liposomal doxorubicin, 5-fluorouracil and cisplatin versus mitomycin-C, 5-fluorouracil and cisplatin for advanced gastric cancer: a randomized phase II trial
    Stefano Cascinu
    Eva Galizia
    Roberto Labianca
    Francesco Ferraù
    Francesca Pucci
    Rosa Rita Silva
    Gabriele Luppi
    Giordano Domenico Beretta
    Rossana Berardi
    Mario Scartozzi
    Cancer Chemotherapy and Pharmacology, 2011, 68 : 37 - 43
  • [27] A Randomized Phase II Trial of Capecitabine Plus Vinorelbine Followed by Docetaxel Versus Adriamycin Plus Cyclophosphamide Followed by Docetaxel as Neoadjuvant Chemotherapy for Breast Cancer
    Yoo, Changhoon
    Kim, Sung-Bae
    Ahn, Jin-Hee
    Kim, Jeong Eun
    Jung, Kyung Hae
    Gong, Gyung-Yub
    Son, Byung-Ho
    Ahn, Sei-Hyun
    Ahn, Seung Do
    Kim, Hak-Hee
    Shin, Hee Jung
    Kim, Woo Kun
    CANCER RESEARCH AND TREATMENT, 2015, 47 (03): : 406 - 415
  • [28] Phase II Trial of Combination of Pegylated Liposomal Doxorubicin, Cisplatin, and Infusional 5-Fluorouracil (CCF) Plus Trastuzumab as Preoperative Treatment for Locally Advanced and Inflammatory Breast Cancer
    Torrisi, Rosalba
    Cardillo, Anna
    Cancello, Giuseppe
    Dellapasqua, Silvia
    Balduzzi, Alessandra
    Ghisini, Raffaella
    Luini, Alberto
    Veronesi, Paolo
    Viale, Giuseppe
    Goldhirsch, Aron
    Colleoni, Marco
    CLINICAL BREAST CANCER, 2010, 10 (06) : 483 - 488
  • [29] Paclitaxel and epirubicin versus paclitaxel and carboplatin as first-line chemotherapy in patients with advanced breast cancer: a phase III study conducted by the Hellenic Cooperative Oncology Group
    Fountzilas, G
    Kalofonos, HP
    Dafni, U
    Papadimitriou, C
    Bafaloukos, D
    Papakostas, P
    Kalogera-Fountzila, A
    Gogas, H
    Aravantinos, G
    Moulopoulos, LA
    Economopoulos, T
    Pectasides, D
    Maniadakis, N
    Siafaka, V
    Briasoulis, E
    Christodoulou, C
    Tsavdaridis, D
    Makrantonakis, P
    Razis, E
    Kosmidis, P
    Skarlos, D
    Dimopoulos, MA
    ANNALS OF ONCOLOGY, 2004, 15 (10) : 1517 - 1526
  • [30] Pegylated Liposomal Doxorubicin, Docetaxel, and Trastuzumab as Neoadjuvant Treatment for HER2-Positive Breast Cancer Patients: A Phase II and Biomarker Study
    Wang, Haoqi
    Li, Yuntao
    Qi, Yixin
    Zhao, Erbao
    Kong, Xiangshun
    Yang, Chao
    Yang, Qiqi
    Zhang, Chengyuan
    Liu, Yueping
    Song, Zhenchuan
    FRONTIERS IN ONCOLOGY, 2022, 12
12345